Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jun 4;12:4245–4252. doi: 10.2147/OTT.S200718

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Liu et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

AR ligand (DHT) promoted the migration of SCC9 cells via increasing EGFR phosphorylation. (A, B, E, F, and I) DHT increased the migration of SCC9 cells following treatment with DHT for 20 h. (C, D, and G–I) DHT did not change the migration of SCC25 cells. (J and K) In SCC9 cells, DHT increased expression of pEGFR and pAKT proteins with no changing of tEGFR mRNA and protein. DHT did not cause any change of tEGFR, pEGFR and pAKT in SCC25 (scale bar, 500 µm).Abbreviations: AR, androgen; EGFR, epidermal growth factor receptor; pEGFR, phosphorylated EGFR; tEGFR, total EGFR.